WO2014136519A1 - Egf受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 - Google Patents
Egf受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 Download PDFInfo
- Publication number
- WO2014136519A1 WO2014136519A1 PCT/JP2014/052673 JP2014052673W WO2014136519A1 WO 2014136519 A1 WO2014136519 A1 WO 2014136519A1 JP 2014052673 W JP2014052673 W JP 2014052673W WO 2014136519 A1 WO2014136519 A1 WO 2014136519A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- atom
- inhibitor
- myocardial differentiation
- Prior art date
Links
- ZWROSJRBDUKKBW-PARFRUBRSA-N CCCOc1ccc(CC/C(/[C@H](C)C(C)c([s]c2c3)nc2ccc3I)=C\C)cc1OC Chemical compound CCCOc1ccc(CC/C(/[C@H](C)C(C)c([s]c2c3)nc2ccc3I)=C\C)cc1OC ZWROSJRBDUKKBW-PARFRUBRSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Definitions
- the present invention relates to a pluripotent stem cell myocardial differentiation promoting agent comprising an EGF receptor inhibitor.
- the present invention also provides a myocardial differentiation promoting kit containing an EGF receptor inhibitor and induction of myocardial differentiation of pluripotent stem cells, comprising culturing pluripotent stem cells in a medium containing an EGF receptor inhibitor. Regarding the method.
- the method for inducing differentiation of pluripotent stem cells is the key to the realization of regenerative medicine and the establishment of in vitro drug efficacy evaluation tests or drug safety tests.
- heart disease is currently the second leading cause of death among Japanese people, and is important for regenerative medicine and evaluation of heart disease efficacy.
- drugs that cause serious side effects such as heart failure and arrhythmia to the heart, there is a demand for a stable supply of uniform cardiomyocytes that can be used in cardiotoxicity tests.
- Non-Patent Document 1 which is included herein by reference.
- Non-patent Documents 2 and 3 which are incorporated herein by reference.
- a method for inducing cardiomyocytes using BMP4, FGF2, insulin and serum has been reported (Non-patent Document 4, which is included herein by reference).
- these methods require a large amount of cytokines and thus increase costs and are not suitable for practical use.
- Non-patent Document 5 a method for inducing cardiomyocytes from mouse ES cells using a tankyrase inhibitor XAV939 has been reported (Non-patent Document 5, which is included herein by reference).
- the induction efficiency is as low as 10-60%, it is difficult to apply to regenerative medicine.
- Patent Documents 1 and 2 have previously reported low molecular weight compounds that promote myocardial differentiation from pluripotent stem cells (Patent Documents 1 and 2, and Non-Patent Document 7, which are included herein by reference). ).
- the epidermal growth factor (EGF) receptor is a tyrosine kinase type receptor having EGF as a ligand, and is important for regulation of cell proliferation, differentiation and maintenance. EGF signaling has been reported to have an important role in heart development (Non-patent document 6, incorporated herein by reference). In addition, EGF receptors are deeply involved in the proliferation and metastasis of cancer cells, and EGF receptor inhibitors such as gefitinib are used as anticancer agents. However, there have been no reports on the application of EGF receptor inhibitors such as gefitinib and AG1478 to myocardial differentiation of human pluripotent stem cells.
- An object of the present invention is to provide a myocardial differentiation promoting agent and method that enable myocardial differentiation of pluripotent stem cells with high efficiency and low cost.
- the present invention provides an agent for promoting myocardial differentiation of pluripotent stem cells, comprising an EGF receptor inhibitor.
- the present invention also provides a kit for promoting myocardial differentiation including an EGF receptor inhibitor.
- the present invention also provides a method for inducing myocardial differentiation of pluripotent stem cells, comprising culturing pluripotent stem cells in a medium containing an EGF receptor inhibitor.
- cardiomyocytes can be produced by inducing myocardial differentiation of pluripotent stem cells with high efficiency and low cost.
- EGF receptor inhibitor (AG1478) promotes myocardial differentiation.
- EGF receptor inhibitor (gefitinib) promotes myocardial differentiation.
- the myocardial differentiation promoting effect of an EGF receptor inhibitor (AG1478 or gefitinib) and the synergistic effect of an EGF receptor inhibitor (AG1478 or gefitinib) and a Wnt signal inhibitor (KY02111 and / or XAV939).
- EGF receptor inhibitor (gefitinib) on myocardial differentiation under conditions free of cytokines and xenogeneic components in human ES cells (KhES-3). Effect of promoting myocardial differentiation of EGF receptor inhibitor (AG1478 or gefitinib) on myocardial differentiation of human ES cells (KhES-3) and iPS cells (IMR90-1) under cytokine and xenogene-free conditions. Synergistic effect of an EGF receptor inhibitor (AG1478 or gefitinib) and a Wnt signal inhibitor (XAV939). Direct myocardial differentiation from sphere culture system of human iPS cells (253G1). Synergistic effect of EGF receptor inhibitor (PP3) and Wnt signal inhibitor (KY02111).
- the pluripotent stem cell myocardial differentiation promoter of the present invention contains an epidermal growth factor (EGF) receptor inhibitor.
- EGF receptor inhibitor in the present invention means any substance that inhibits signal transduction from the EGF receptor and includes, but is not limited to, low molecular weight compounds, nucleic acids, peptides, antibodies and the like.
- EGF receptor inhibitors examples include AG1478, Gefitinib, Afatinib, ARRY334543, AST1306, AZD8931, BIBU1361, BIBX1382, BPQ, BPIQ-I, BPIQ-II, Canertinib5, Canertinib78 CUDC101, Dacomitinib, Vandetanib, EGFR Inhibitor III (N- (4-((3,4-dichloro-6-fluorophenyl) amino) -quinazolin-6-yl) -2-chloroacetamide, CAS 733009-42-2), EGFR / ErbB-2 Inhibitor (4- (4-benzyloxyanilino) -6,7-dimethoxyquinazoline, CAS 179248-61-4), Erlotinib, GW583340, GW2974, HDS029, Lapatinib, W I-P154, OSI-420, PD153035,
- the EGF receptor inhibitor is an EGF receptor inhibitor having a quinazoline-based skeleton, such as AG1478, gefitinib, afatinib, ARRY334543, AST1306, AZD8931, BIBU1361, BIBX1382, BPDQ, BPIQ-I, BPIQ-II, Caneltinib CL-387,785, CUDC101, dacomitinib, vandetanib, EGFR Inhibitor III (CAS 733009-42-2), EGFR / ErbB-2 Inhibitor (CAS 179248-61-4), erlotinib, GW58340, GW2974, HDS029, lapatinib, WHI-P154, OSI-420, PD153035, PD168393, PD174265, peritinib, Compound 56, XL657, or PP3.
- Preferred EGF receptor inhibitors for the present invention are AG1478, gefitinib,
- the term “pluripotent stem cell” means pluripotency capable of differentiating into all cells constituting an adult and self-replication capable of maintaining the pluripotency even after cell division. It means a cell having the ability.
- the “pluripotent stem cell” includes embryonic stem cells (ES cells), embryonic germ cells (EG cells), and induced pluripotent stem cells (iPS cells).
- the species of “pluripotent stem cells” is not particularly limited, but is preferably a mammal, more preferably a rodent or a primate.
- the present invention is particularly suitable for monkey or human pluripotent stem cells.
- ES cells are pluripotent stem cells derived from early embryos, and can be established from the inner cell mass of blastocysts or epiblasts of early embryos after implantation.
- ES cells include humans (Thomson J. A. et al., Science 282: 1145-1147 (1998), Biochem Biophys Res Commun. 345 (3), 926-32 (2006); primates such as rhesus monkeys and marmosets (Thomson J. A. et al., Proc. Natl. Acad. Sci. USA 92: 7844-7848 (1995); Thomson J. A. et al., Biol. Reprod.
- EG cells are pluripotent stem cells derived from primordial germ cells, such as human EG cells (Shamblott, et al., Proc. Natl. Acad. Sci USA 95: 13726-13731 (1998)) Included in the specification).
- iPS cell means a pluripotent stem cell derived from a cell other than a pluripotent stem cell such as a somatic cell or a tissue stem cell.
- the method for producing iPS cells is, for example, WO2007 / 069666, WO2009 / 006930, WO2009 / 006997, WO2009 / 007852, WO2008 / 118820, Cell Stem Cell 3 (5): 568-574 (2008), Cell Stem Cell 4 (5 ): 381-384 (2009), Nature 454: 646-650 (2008), Cell 136 (3): 411-419 (2009), Nature Biotechnology 26: 1269-1275 (2008), Cell Stem Cell 3: 475- 479 (2008), Nature Cell Biology 11: 197-203 (2009), Cell 133 (2): 250-264 (2008), Cell 131 (5): 861-72 (2007), Science 318 (5858): 1917 -20 2007 (2007) (both included herein by reference).
- cells produced by any method are included in the “iPS
- the myocardial differentiation promoting agent of the present invention may be used in combination with another myocardial differentiation promoting factor such as a Wnt signal inhibitor, a Wnt signal activator, nitrobin, or a cytokine (a combination of bFGF, BMP4, VEGF, DKK1, and activin A).
- a Wnt signal inhibitor such as a Wnt signal inhibitor, a Wnt signal activator, nitrobin, or a cytokine (a combination of bFGF, BMP4, VEGF, DKK1, and activin A).
- a cytokine a combination of bFGF, BMP4, VEGF, DKK1, and activin A.
- the “myocardial differentiation promoting factor” in the present invention includes all substances having a myocardial differentiation promoting effect.
- the myocardial differentiation promoter of the present invention is used in combination with a Wnt signal inhibitor and / or a Wnt signal activator.
- the “Wnt signal activator” in the present invention means a substance that activates the Wnt signal pathway.
- Wnt signal activators include GSK3 ⁇ inhibitors such as BIO and CHIR99021.
- GSK3 ⁇ inhibitors such as BIO and CHIR99021.
- two or more, for example 2, 3, or 4 types of Wnt signal activators may be used in combination.
- Wnt signal inhibitor in the present invention means a substance that inhibits the Wnt signal pathway.
- Wnt signal inhibitors include, for example, the following compounds of formula (I) or salts thereof, compounds such as IWP2, XAV939, and IWR1, and proteins such as IGFBP4 and Dkk1.
- the Wnt signal inhibitor in the present invention is a compound, for example, a compound of formula (I) or a salt thereof, IWP2, XAV939, and IWR1.
- two or more, for example 2, 3, or 4 types of Wnt signal inhibitors may be used in combination.
- the Wnt signal inhibitor is a compound of the following formula (I) or a salt thereof: Formula (I): [Where: R 1 to R 5 each independently represent a hydrogen atom; a halogen atom; a hydroxyl group; a straight or branched alkoxy group having 1 to 5 carbon atoms; a straight chain having 1 to 5 carbon atoms that is unsubstituted or substituted with a halogen atom.
- R 12 and R 13 are each independently a straight chain of 1 to 5 carbon atoms substituted with a hydrogen atom, an oxygen atom, or an unsubstituted or halogen atom, or Where two adjacent R 1 —R 5 together form —O—CH 2 —O— or —O— (CH 2 ) 2 —O—.
- R 6 to R 9 each independently represent a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; and a 1 to 5 carbon atom substituted with a group —C (O) A.
- a straight-chain or branched alkoxy group (A is a saturated or unsaturated 5- or 6-membered ring which is unsubstituted or substituted with a straight-chain or branched alkyl group having 1 to 5 carbon atoms, and the ring is a nitrogen atom, an oxygen atom, And 1 or 2 atoms independently selected from a sulfur atom); a straight-chain or branched alkyl group of 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom; or a group —NR 12 R 13 (R 12 and R 13 each independently represents a hydrogen atom, an oxygen atom, or a linear or branched alkyl group having 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom), Although in two adjacent of R 6 -R 9 together O-CH 2 -O- or -O- (CH 2) may form a 2 -O-, R 10 to R 11 are each independently
- linear or branched alkoxy group having 1 to 5 carbon atoms examples include methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, and pentyloxy group. Can be mentioned.
- Examples of the linear or branched alkyl group having 1 to 5 carbon atoms include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, and a pentyl group. .
- linear or branched acyl group having 1 to 5 carbon atoms examples include formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, and isovaleryl group.
- each of R 1 to R 5 independently represents a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or an unsubstituted or substituted carbon atom having 1 carbon atom.
- R 1 to R 5 independently represents a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or an unsubstituted or substituted carbon atom having 1 carbon atom.
- R 2 and R 3 are preferably straight-chain or branched alkoxy groups having 1 to 5 carbon atoms, or together, —O—CH 2 —O— or —O— (CH 2 ) 2 —. O- is formed. More preferably, R 2 and R 3 are a methoxy group, an ethoxy group, or a propoxy group. Even more preferably, R 2 is a methoxy group and R 3 is a methoxy group, an ethoxy group, or a propoxy group.
- R 1 , R 4 and R 5 are preferably hydrogen atoms.
- R 6 to R 9 each independently represent a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; an unsubstituted or substituted carbon atom having 1 to 5 carbon atoms; Or a group —NR 12 R 13 (wherein R 12 and R 13 each independently represents a hydrogen atom, an oxygen atom, or an unsubstituted or substituted carbon atom having 1 to 5 carbon atoms) Where two adjacent R 6 —R 9 together are —O—CH 2 —O— or —O— (CH 2 ) 2 —O - May be formed.
- R 6 and R 9 are preferably each independently a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or an unsubstituted or substituted carbon atom having 1 to 5 carbon atoms.
- 5 is a linear or branched alkyl group, and more preferably a hydrogen atom.
- R 7 represents a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; a linear or branched group having 1 to 5 carbon atoms substituted with a group —C (O) A.
- An alkoxy group (A is a saturated or unsaturated 5- or 6-membered ring which is unsubstituted or substituted by a linear or branched alkyl group having 1 to 5 carbon atoms, and the ring is formed from a nitrogen atom, an oxygen atom, and a sulfur atom; 1 or 2 atoms independently selected); a linear or branched alkyl group of 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom; or a group —NR 12 R 13 (R 12 and R 13 are each independently a hydrogen atom, an oxygen atom, or a linear or branched alkyl group having 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom, and R 8 is Hydrogen atom; halogen atom; hydroxyl group; carbon number 1 5 straight or branched alkoxy group; or unsubstituted or a straight-chain or branched alkyl group of
- R 7 is a halogen atom.
- R 7 is a linear alkoxy group having 1 to 5 carbon atoms substituted with a group —C (O) A, and the group —C (O) A is bonded to the terminal carbon atom of the alkoxy group. is doing.
- A contains at least one nitrogen atom, and such A includes pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolyl, imidazolyl, which is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms.
- Pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, piperidinyl, piperazinyl, morpholinyl, pyridyl, pyrimidinyl, pyrazinyl, and pyridazinyl groups are examples of the group.
- A is a piperidinyl group, piperazinyl group, or morpholinyl group that is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms.
- A is a piperidin-1-yl group, piperazin-1-yl group, or morpholin-4-yl group which is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms. is there.
- R 10 and R 11 are preferably a hydrogen atom.
- X is an oxygen atom; a sulfur atom; a group —NR 15 (wherein R 15 is a hydrogen atom, a linear or branched alkyl group having 1 to 5 carbon atoms, a linear or branched acyl group having 1 to 5 carbon atoms). Is). X is preferably a sulfur atom.
- n is an integer from 0 to 4. In a further preferred embodiment, n is an integer from 1 to 3, even more preferably 2 or 3.
- Examples of the compound of the formula (I) or a salt thereof in the present invention include the following compounds or salts thereof: (1) Formula (I): [Where: R 1 to R 5 each independently represent a hydrogen atom; a halogen atom; a hydroxyl group; a straight or branched alkoxy group having 1 to 5 carbon atoms; a straight chain having 1 to 5 carbon atoms that is unsubstituted or substituted with a halogen atom.
- R 12 and R 13 are each independently a straight chain of 1 to 5 carbon atoms substituted with a hydrogen atom, an oxygen atom, or an unsubstituted or halogen atom, or Where two adjacent R 1 —R 5 together form —O—CH 2 —O— or —O— (CH 2 ) 2 —O—.
- R 6 to R 9 each independently represent a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; and a 1 to 5 carbon atom substituted with a group —C (O) A.
- a straight-chain or branched alkoxy group (A is a saturated or unsaturated 5- or 6-membered ring which is unsubstituted or substituted with a straight-chain or branched alkyl group having 1 to 5 carbon atoms, and the ring is a nitrogen atom, an oxygen atom, And 1 or 2 atoms independently selected from a sulfur atom); a straight-chain or branched alkyl group of 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom; or a group —NR 12 R 13 (R 12 and R 13 each independently represents a hydrogen atom, an oxygen atom, or a linear or branched alkyl group having 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom), Although in two adjacent of R 6 -R 9 together O-CH 2 -O- or -O- (CH 2) may form a 2 -O-, R 10 to R 11 are each independently
- R 6 -R 9 each independently represents a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; an unsubstituted or substituted carbon atom having 1 to 5 carbon atoms. Or a group —NR 12 R 13 (wherein R 12 and R 13 each independently represents a hydrogen atom, an oxygen atom, or an unsubstituted or substituted carbon atom having 1 to 5 carbon atoms) Wherein two adjacent R 6 —R 9 are taken together to form —O—CH 2 —O— or —O— (CH 2 ) 2 —O—.
- R 1 to R 5 are each independently a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or an unsubstituted or substituted carbon atom having 1 to 5 carbon atoms. 5 linear or branched alkyl groups, wherein two adjacent R 1 —R 5 together form —O—CH 2 —O— or —O— (CH 2 ) 2 —O—.
- X is an oxygen atom; a sulfur atom; a group —NR 15 (wherein R 15 is a hydrogen atom, a linear or branched alkyl group having 1 to 5 carbon atoms, or a linear chain having 1 to 5 carbon atoms) Or a branched acyl group) or the salt thereof according to (2).
- R 2 and R 3 are linear or branched alkoxy groups having 1 to 5 carbon atoms, or R 2 and R 3 together are —O—CH 2 —O— or —O— ( CH 2 ) 2 —O— is formed, R 6 and R 9 are each independently a hydrogen atom; a halogen atom; a hydroxyl group; a straight-chain or branched alkoxy group having 1 to 5 carbon atoms; or an unsubstituted or straight chain having 1 to 5 carbon atoms substituted with a halogen atom.
- a chain or branched alkyl group, and R 7 is a hydrogen atom; a halogen atom; a hydroxyl group; a straight-chain or branched alkoxy group having 1 to 5 carbon atoms; a straight chain having 1 to 5 carbon atoms that is unsubstituted or substituted with a halogen atom.
- R 8 is a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or a linear or branched alkyl group having 1 to 5 carbon atoms that is unsubstituted or substituted with a halogen atom. Or the compound or a salt thereof according to (3), wherein R 7 and R 8 together form —O—CH 2 —O— or —O— (CH 2 ) 2 —O—.
- R 1 , R 4 , R 5 , R 6 , R 9 , R 10 and R 11 are hydrogen atoms
- R 2 and R 3 are a methoxy group, an ethoxy group, or a propoxy group
- X is a sulfur atom
- n is an integer of 0 to 4.
- R 7 is a halogen atom
- R 8 is a hydrogen atom.
- R 2 is a methoxy group
- R 3 is a methoxy group, an ethoxy group, or a propoxy group.
- R 1 , R 4 , R 5 , R 6 , R 8 , and R 9 are each independently a hydrogen atom; a halogen atom; a hydroxyl group; a linear or branched alkoxy group having 1 to 5 carbon atoms; or A linear or branched alkyl group having 1 to 5 carbon atoms which is unsubstituted or substituted with a halogen atom, R 2 and R 3 are linear or branched alkoxy groups having 1 to 5 carbon atoms, or R 2 and R 3 together represent —O—CH 2 —O— or —O— (CH 2 ).
- R 7 is a linear or branched alkoxy group having 1 to 5 carbon atoms substituted with a group —C (O) A (A is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms) A saturated or unsaturated 5- or 6-membered ring, which ring may contain 1 or 2 atoms independently selected from nitrogen, oxygen and sulfur atoms), and X is An oxygen atom; a sulfur atom; a group —NR 15 (wherein R 15 is a hydrogen atom, a linear or branched alkyl group having 1 to 5 carbon atoms, or a linear or branched acyl group having 1 to 5 carbon atoms).
- R 1 , R 4 , R 5 , R 6 , R 8 , and R 9 are hydrogen atoms
- R 2 and R 3 are a methoxy group, an ethoxy group, or a propoxy group
- R 10 and R 11 are hydrogen atoms
- X is a sulfur atom
- A is a piperidinyl group, piperazinyl group, or morpholinyl group that is unsubstituted or substituted with a linear or branched alkyl group having 1 to 5 carbon atoms
- n is an integer of 0 to 4, (11) Or a salt thereof.
- the compound of formula (I) or salt thereof is the following compound or salt thereof: and, [Wherein R 7 represents a halogen atom. ].
- a suitable Wnt signal inhibitor in the present invention is a compound selected from the following or a salt thereof: KY02111 KY010104 T61164 KY02114 KY01045 KY01040 KY02109 KY010104 KY01043 KY01046 PB2852 N11474 PB2572 PB2570 KY02104 SO087 SO102 SO096 SO094 SO3031 (KY01-I) SO2031 (KY02-I) SO3042 (KY03-I) SO2077
- Particularly preferred compounds of the formula (I) or salts thereof according to the invention are compounds or salts thereof selected from: KY02111 KY010104 T61164 KY02114 KY01045 KY02104 SO087 SO102 SO3031 (KY01-I) SO2031 (KY02-I) SO3042 (KY03-I) SO2077
- the myocardial differentiation promoter of the present invention can be used according to the cardiomyocyte induction method for pluripotent stem cells of the present invention described later.
- the myocardial differentiation promotion kit of the present invention contains an EGF receptor inhibitor.
- the kit for promoting myocardial differentiation of the present invention may further contain a Wnt signal inhibitor, a Wnt signal activator and other myocardial differentiation promoting factors.
- the method for inducing cardiomyocytes of pluripotent stem cells of the present invention includes culturing pluripotent stem cells in a medium containing an EGF receptor inhibitor.
- the present invention is practiced in vitro.
- the medium used in the method of the present invention may be a medium generally used for myocardial differentiation of pluripotent stem cells (hereinafter also referred to as myocardial differentiation medium), and its composition is not particularly limited.
- a myocardial differentiation medium based on IMDM medium for example, a medium used in Examples
- a myocardial differentiation medium based on DMEM for example, DMEM / F12 medium (Sigma)
- DMEM for example, DMEM / F12 medium (Sigma)
- GEBCO fetal bovine serum
- MEM non-essential amino acid solution Sigma
- penicillin-streptomycin GBCO
- StemPro A medium such as -34 SFM (GIBCO) + BMP4 (10 ng / ml) is exemplified.
- the present invention provides a method for inducing cardiomyocyte pluripotent stem cells using a serum-free medium (hereinafter also referred to as a serum-free medium).
- a serum-free medium preferably contains albumin.
- albumin include bovine serum albumin and human serum albumin.
- serum, cytokines, feeder cells (feeder cells) and other proteins other than albumin and components derived from biological species different from the pluripotent stem cells used (ie, heterogeneous components) Can induce myocardial differentiation of pluripotent stem cells.
- a culture method generally suitable for myocardial differentiation of pluripotent stem cells can be used.
- the culture method include an adhesion culture method, a suspension culture method, and a suspension culture method.
- the methods of the invention do not use feeder cells (feeder cells) such as END2 cells.
- a period from the start of culture in a myocardial differentiation medium (hereinafter also referred to as myocardial differentiation culture) to the start of culture in a medium containing an EGF receptor inhibitor, and in the medium containing an EGF receptor inhibitor
- the culture period in can be changed as appropriate.
- two or more days from the second, third, or fourth to fourteenth days of myocardial differentiation culture (specifically, 2, 3, 4, 5 6, 7, 8, 9, 10, 11, or 12 days), preferably 3 to 10 days, more preferably 4 to 10 days, and even more preferably 4 to 8 days.
- 4 to 8 days out of days 2, 3, or 4 to 10 of myocardial differentiation culture for example, 2 to 10 days (8 days) and 2 to 9 days (7 days) of myocardial differentiation culture Days 2-8 (6 days), 3-10 days (7 days), 3-9 days (6 days), 3-8 days (5 days), 4-10 days (6 days) It is preferably carried out on the 4th to 9th days (5 days) and on the 4th to 8th days (4 days).
- the method of the present invention may further comprise culturing pluripotent stem cells in a medium containing a Wnt signal activator and / or culturing pluripotent stem cells in a medium containing a Wnt signal inhibitor. .
- the method of the present invention includes the step of culturing pluripotent stem cells in a medium containing an EGF receptor inhibitor and a Wnt signal inhibitor.
- the method in addition to the step of culturing pluripotent stem cells in a medium containing an EGF receptor inhibitor and a Wnt signal inhibitor, the method is carried out in a medium containing either an EGF receptor inhibitor or a Wnt signal inhibitor.
- the step of culturing the cells may be included. For example, after culturing cells in a medium containing an EGF receptor inhibitor and not containing a Wnt signal inhibitor, or a medium containing a Wnt signal inhibitor and not containing an EGF receptor inhibitor, the medium is treated with EGF receptor.
- the medium may be replaced with a medium containing both a body inhibitor and a Wnt signal inhibitor, and the culture may be continued.
- a medium containing both an EGF receptor inhibitor and a Wnt signal inhibitor during the entire culture period may be used. Further, after culturing in a medium containing both an EGF receptor inhibitor and a Wnt signal inhibitor, there may be a period in which cells are cultured in a medium containing only one of them.
- the methods of the invention include the following steps: (1) culturing pluripotent stem cells in a medium containing a Wnt signal activator; and (2) A step of culturing the cells in a medium containing an EGF receptor inhibitor after the step (1).
- the period from the start of myocardial differentiation culture to the start of step (1), the period from the end of step (1) to the start of step (2), and the culture period of steps (1) and (2) It can be changed appropriately.
- Step (2) may be started immediately after the end of step (1), or may be started after a certain period from the end of step (1).
- the Wnt signal activator may be added to the initial stage of myocardial differentiation of pluripotent stem cells.
- the initial stage of myocardial differentiation of pluripotent stem cells means a differentiation induction phase from pluripotent stem cells to mesoderm in which expression of a mesoderm marker gene occurs. Differentiation into mesoderm can be determined by examining the expression of a mesoderm marker gene. Examples of mesoderm marker genes include T, MIXL1, NODAL and the like.
- step (1) is performed on days 0 to 2 or 0 to 3 of myocardial differentiation culture, that is, 2 or 3 days from the start of myocardial differentiation culture, , More than 2 days out of the 2nd, 3rd, or 4th to 14th days of myocardial differentiation culture (specifically 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 days), preferably 3 to 10 days, more preferably 4 to 10 days, and even more preferably 4 to 8 days.
- Step (2) is, for example, 4 to 8 days from 2, 3, or 4 to 10 days of myocardial differentiation culture, for example, 2 to 10 days (8 days) of myocardial differentiation culture, 2 to 9 Day (7 days), 2-8 days (6 days), 3-10 days (7 days), 3-9 days (6 days), 3-8 days (5 days), 4-10 It is preferable to carry out the treatment on the day (6 days), the 4th to 9th days (5 days), or the 4th to 8th days (4 days).
- the cells are cultured in a medium further containing a Wnt signal inhibitor in addition to the EGF receptor inhibitor.
- the Wnt signal inhibitor may be added to the middle stage of myocardial differentiation of pluripotent stem cells.
- the intermediate stage of myocardial differentiation of pluripotent stem cells means the stage of induction of differentiation from mesoderm to cardiomyocytes. Differentiation into cardiomyocytes can be confirmed by the number of beating cardiomyocytes, expression of myocardial markers, expression of ion channels, response to electrophysiological stimulation, and the like.
- Myocardial markers include ⁇ MHC, ⁇ MHC, cTnT, ⁇ -actinin, and NKX2.5.
- Examples of the ion channel include HCN4, Nav1.5, Cav1.2, Cav3.2, HERG1b, and KCNQ1.
- the medium is a medium containing an EGF receptor inhibitor and a Wnt signal inhibitor. And continue the culture.
- a medium containing both an EGF receptor inhibitor and a Wnt signal inhibitor may be used throughout the culture period of step (2).
- the medium is replaced with a medium containing an EGF receptor inhibitor and a Wnt signal inhibitor, May be continued.
- the concentration of the EGF receptor inhibitor in the present invention is not particularly limited.
- gefitinib or AG1478 is used as an EGF receptor inhibitor, it may be used at a final concentration of 100 nM to 100 ⁇ M, preferably 1 ⁇ M to 20 ⁇ M.
- PP3 is used as an EGF receptor inhibitor, it may be used at a final concentration of 1 ⁇ M to 1 mM, preferably 10 ⁇ M to 100 ⁇ M.
- the concentration of the Wnt signal activator and the Wnt signal inhibitor in the present invention is not particularly limited.
- BIO or CHIR99021 is used as the Wnt signal activator, it may be used at a final concentration of 100 nM to 100 ⁇ M, preferably 1 ⁇ M to 10 ⁇ M.
- IWP2, XAV939, or IWR1 is used as the Wnt signal inhibitor, for example, it may be used at a final concentration of 0.5 to 20 ⁇ M, preferably 1 to 10 ⁇ M.
- a final concentration of 0.1 to 20 ⁇ M, preferably 0.1 to 10 ⁇ M, more preferably 1 to What is necessary is just to use at 10 micromol.
- the method of the present invention can be used for the production of cardiomyocytes.
- Obtaining cardiomyocytes can be confirmed by the number of beating cardiomyocytes, expression of myocardial markers, expression of ion channels, response to electrophysiological stimulation, and the like.
- the cardiomyocytes obtained by the method of the present invention can be used for in vitro drug safety tests or as transplanted cardiomyocytes for heart disease and the like.
- the present invention provides a pluripotent stem cell myocardial differentiation promoter comprising the compound of formula (I) or a salt thereof, which is used in combination with an EGF receptor inhibitor.
- the compound of the formula (I) or a salt thereof and the EGF receptor inhibitor in this embodiment are as described for the “promoting agent for myocardial differentiation of pluripotent stem cells, including an EGF receptor inhibitor”.
- the present invention relates to the use of an EGF receptor inhibitor for promoting myocardial differentiation of pluripotent stem cells, and the use of an EGF receptor inhibitor for the manufacture of an agent for promoting myocardial differentiation of pluripotent stem cells.
- an EGF receptor inhibitor for promoting myocardial differentiation of pluripotent stem cells and the use of an EGF receptor inhibitor for the manufacture of an agent for promoting myocardial differentiation of pluripotent stem cells.
- Seed in 6-well plate (CORNING 3261) of Ultra-low culture dish, and mTeSR1 medium (Stem Cell Technology 05850) containing 3% methylcellulose (R & D, HSC001) will increase the size of iPS cell colonies to about 200-300 ⁇ m Until suspension culture.
- IMDM IMDM (Sigma) (1% MEM non-essential amino acid solution ( Sigma), 1% penicillin-streptomycin (Gibco), 2 mM L-glutamine (Sigma), 0.5 mM L-carnitine (Sigma), 0.001% 2-mercaptoethanol (Gibco), and 0.4% human serum albumin (Sigma) )
- IMDM IMDM (Sigma) (1% MEM non-essential amino acid solution ( Sigma), 1% penicillin-streptomycin (Gibco), 2 mM L-glutamine (Sigma), 0.5 mM L-carnitine (Sigma), 0.001% 2-mercaptoethanol (Gibco), and 0.4% human serum albumin (Sigma) )
- CHIR99021 (4 ⁇ M) and BIO (1 ⁇ M) were added on days 0 to 2 (2 days) and cultured for 3 to 9 days.
- EY02111 (10 ⁇ M) and XAV939 (1 ⁇ M) were added to the eyes (6 days)
- EGF receptor inhibitor AG1478 or Gefiti Nibs were added at a concentration of 10 ⁇ M on days 3 to 9 (6 days)
- Myocardial differentiation was effected on the 30th day of culture using an antibody against myocardial specific marker cardiac troponin T (cTnT). The ratio of cardiomyocytes was analyzed and evaluated.
- the proportion of cardiomyocytes induced to increase increased from 34% to nearly 50% (FIG. 9). That is, it was found that the EGF receptor inhibitor has an effect of enhancing myocardial differentiation efficiency not only on human iPS cells on mouse feeder cells but also on iPS cells in a feeder-free sphere culture system.
- PP3 is an EGFR inhibitor that has a different skeletal structure from AG1478 and gefitinib, and does not have an inhibitory effect on Src kinase that phosphorylates EGFR, so this result is a substance that inhibits signal transduction from the EGF receptor. Has an effect of promoting myocardial differentiation.
- reaction mixture was diluted with ethyl acetate and washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution.
- the extract was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was recrystallized from ethanol to obtain 167 mg of 2- (2- (3,4-dimethoxyphenyl) acetamido) -6-iodobenzothiazole in a yield of 50%.
- reaction mixture was diluted with ethyl acetate and washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution.
- the extract was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was recrystallized from ethanol to obtain 83 mg of 2- (3- (3,4-dimethoxyphenyl) propanamide) -6-iodobenzothiazole in a yield of 48%.
- reaction mixture was diluted with ethyl acetate and washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution.
- the extract was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was recrystallized from ethanol to obtain 131 mg of 2- (4- (3,4-dimethoxyphenyl) butanamide) -6-iodobenzothiazole in a yield of 30%.
- reaction mixture was diluted with ethyl acetate and washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution.
- the extract was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was recrystallized from ethanol to obtain 217 mg of 2- (3- (3-methoxy-4-propoxyphenyl) propanamide) -6-iodobenzothiazole in a yield of 60%.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
式(I):
R1-R5は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR1-R5のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R6-R9は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR6-R9のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R10-R11は、各々独立して、水素原子;又は炭素数1~5の直鎖又は分岐アルキル基である、
Xは、-CR14(R14は、水素原子、ハロゲン原子、水酸基、炭素数1~5の直鎖又は分岐アルコキシ基、非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である);酸素原子;硫黄原子;セレン原子;又は基-NR15(R15は、水素原子、炭素数1~5の直鎖又は分岐アルキル基、又は炭素数1~5の直鎖又は分岐アシル基である)である、および
nは、0から6の整数である]。
(1)式(I):
R1-R5は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR1-R5のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R6-R9は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR6-R9のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R10-R11は、各々独立して、水素原子;又は炭素数1~5の直鎖又は分岐アルキル基である、
Xは、-CR14(R14は、水素原子、ハロゲン原子、水酸基、炭素数1~5の直鎖又は分岐アルコキシ基、非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である);酸素原子;硫黄原子;セレン原子;又は基-NR15(R15は、水素原子、炭素数1~5の直鎖又は分岐アルキル基、又は炭素数1~5の直鎖又は分岐アシル基である)である、および
nは、0から6の整数である]の化合物またはその塩。
(2)R6-R9が、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR6-R9のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、(1)に記載の化合物またはその塩。
(3)R1-R5が、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である、ここでR1-R5のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、および
Xが、酸素原子;硫黄原子;基-NR15(R15は、水素原子、炭素数1~5の直鎖又は分岐アルキル基、又は炭素数1~5の直鎖又は分岐アシル基である)である、(2)に記載の化合物またはその塩。
(4)R2及びR3が、炭素数1~5の直鎖又は分岐アルコキシ基である、又はR2及びR3が、一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成している、
R6及びR9が、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である、および
R7が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である)である、
R8が、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である、
又は、R7及びR8が、一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成している、(3)に記載の化合物またはその塩。
(5)R1、R4、R5、R6、R9、R10及びR11が、水素原子である、
R2及びR3が、メトキシ基、エトキシ基、又はプロポキシ基である、
Xが、硫黄原子である、および
nが、0から4の整数である、(4)に記載の化合物またはその塩。
(6)R7が、ハロゲン原子であり、R8が、水素原子である、(5)に記載の化合物またはその塩。
(7)R2が、メトキシ基である、および
R3が、メトキシ基、エトキシ基、又はプロポキシ基である、(5)または(6)に記載の化合物またはその塩。
(8)nが、1から3の整数である、(5)~(7)のいずれかに記載の化合物またはその塩。
(9)R1、R4、R5、R6、R8、及びR9が、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である、
R2及びR3が、炭素数1~5の直鎖又は分岐アルコキシ基である、又はR2及びR3が、一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成している、
R7が、基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい)である、および
Xが、酸素原子;硫黄原子;基-NR15(R15は、水素原子、炭素数1~5の直鎖又は分岐アルキル基、又は炭素数1~5の直鎖又は分岐アシル基である)である、(1)に記載の化合物またはその塩。
(10)R1、R4、R5、R6、R8、及びR9が、水素原子である、
R2及びR3が、メトキシ基、エトキシ基、又はプロポキシ基である、
R10及びR11が、水素原子である、
Xが、硫黄原子である、
Aが、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された、ピペリジニル基、ピペラジニル基、又はモルホリニル基である、および
nが、0から4の整数である、(11)に記載の化合物またはその塩。
KY02111
KY02111
(1)多能性幹細胞をWntシグナル活性化剤を含む培地中で培養する工程、および;
(2)工程(1)の後、前記細胞をEGF受容体阻害剤を含む培地中で培養する工程。
前記方法において、心筋分化培養の開始から工程(1)の開始までの期間、工程(1)の終了から工程(2)の開始までの期間、および工程(1)および(2)の培養期間は適宜変更されうる。工程(2)は、工程(1)の終了直後から開始してもよいし、工程(1)の終了から一定期間後に開始してもよい。Wntシグナル活性化剤は、多能性幹細胞の心筋分化の初期段階に添加すればよい。ここで、多能性幹細胞の心筋分化の初期段階とは、中胚葉マーカー遺伝子の発現上昇が起こる、多能性幹細胞から中胚葉への分化誘導期を意味する。中胚葉への分化は、中胚葉マーカー遺伝子の発現を調べることにより決定することができる。中胚葉マーカー遺伝子としては、T、MIXL1、NODAL等が挙げられる。
心筋分化マーカーであるα-MHC遺伝子のプロモータを持つGFP遺伝子を導入したサルES細胞を6ウェルプレート(旭硝子/ 5816-006 :Ezviewカルチャープレート)上に播種(2.0×105細胞/ウェル)し、IMDM培地を基本とした20%FBS(GIBCO 10099-141)含有心筋分化培地(IMDM (Sigma) (20% FBS (Gibco)、1% MEM 非必須アミノ酸溶液 (Sigma)、1% ペニシリン-ストレプトマイシン (Gibco)、2 mM L-グルタミン (Sigma)、0.001% 2-メルカプトエタノール (Gibco)、および0.005N NaOH含有))で培養した。培養4~8日目に、KY02111(10μM)と、EGF受容体阻害剤であるAG1478または下記のキナーゼ阻害剤のいずれかを投与した。
SB203580(20μM):p38MAPK阻害剤
BIRB796(10μM):p38MAPK阻害剤(SBよりもp38阻害活性が強い。)
U0126(10μM):ERK/MAPKK(MEKK)阻害剤
ODQ(20μM):NO感受性グアニル酸シクラーゼ阻害剤(NOによるcGMP産生を阻害する。)
チロホスチンAG490(5μM):JAK2/3阻害剤
AG1478(20μM):EGF受容体チロシンキナーゼおよびErb-B2受容体阻害剤
培養10日目にGFP蛍光量が増加している化合物を、HCS(high contents screening)システム(オリンパスIX81倒立顕微鏡およびモレキュラーデバイス/MetaMorph イメージングシステム)を用いてGFP蛍光量を測定することで検出した。
マウスフィーダー細胞で継代維持したヒトES細胞またはiPS細胞を回収し、そのヒトES細胞またはiPS細胞コロニー(3-10×106細胞/ウェル)を、Ultra-lowカルチャーディッシュの6ウェルプレート(CORNING 3261)に播種し、IMDMを基本とした既知組成培地(IMDM (Sigma)(1% MEM 非必須アミノ酸溶液 (Sigma)、1% ペニシリン-ストレプトマイシン (Gibco)、2 mM L-グルタミン (Sigma)、0.5 mM L-カルニチン (Sigma)、0.001% 2-メルカプトエタノール (Gibco)、および0.4% ヒト血清アルブミン (Sigma)含有))を用いて浮遊培養で30日間培養した(図5)。培養0~2日目に(2日間)CHIR99021(Axon)(4μM)とBIO(Calbiochem)(1μM)を添加し、培養3~9日目に(6日間)KY02111(10μM)とXAV939(1μM)を添加した。また、KY02111とXAV939に加えて、EGF受容体阻害剤であるAG1478あるいはゲフィチニブを、5~20μMの濃度で、培養0~2日目(2日間)、2~5日目(3日間)、3~7日目(4日間)、あるいは2~9日目(7日間)添加した。心筋分化効果は、培養30日目に、心筋特異的マーカーである心筋トロポニンT(cTnT)に対する抗体を用いたフローサイトメトリーにより心筋細胞の割合を解析して評価した。
ヒトiPS細胞株(253G1)に対して支持細胞なし(フィーダーフリー)のスフェア培養を行った。具体的には、マウスフィーダー細胞で継代維持した253G1細胞を回収し、その細胞塊を50μmのメッシュ(CellTrics, PARTEC04004-2327)に通して均一な細胞塊(80-120μm)を得た後、Ultra-lowカルチャーディッシュの6ウェルプレート(CORNING 3261)に播種し、3%メチルセルロース(R&D, HSC001)を含んだmTeSR1培地(Stem Cell Technology 05850)でiPS細胞コロニーの大きさが約200-300μmになるまで浮遊培養した。このフィーダーフリーのスフェア培養法を用いて上記の手順を繰り返すことで20継代以上培養維持した細胞に対し、IMDMを基本とした既知組成培地(IMDM (Sigma)(1% MEM 非必須アミノ酸溶液 (Sigma)、1% ペニシリン-ストレプトマイシン (Gibco)、2 mM L-グルタミン (Sigma)、0.5 mM L-カルニチン (Sigma)、0.001% 2-メルカプトエタノール (Gibco)、および0.4% ヒト血清アルブミン (Sigma)含有)を培地交換によりそのまま添加し、浮遊培養で30日間培養した(図5)。培養0~2日目に(2日間)CHIR99021(4μM)とBIO(1μM)を添加し、培養3~9日目に(6日間)KY02111(10μM)とXAV939(1μM)を添加した。また、KY02111とXAV939に加えて、EGF受容体阻害剤であるAG1478あるいはゲフィチニブを、10μMの濃度で、3~9日目(6日間)添加した。心筋分化効果は、培養30日目に、心筋特異的マーカーである心筋トロポニンT(cTnT)に対する抗体を用いたフローサイトメトリーにより心筋細胞の割合を解析して評価した。
上記1と同様にして、サルES細胞においてEGF受容体阻害剤であるPP3のの心筋分化促進効果を検討した。培養4~8日目に、KY02111(10μM)と、PP3(3μM、10μM、30μM、または100μM)を投与した。その結果、PP3はKY02111の心筋分化促進効果を増強することが分かった(図10)。PP3は、AG1478やゲフィチニブと骨格構造が異なること、またEGFRをリン酸化するSrcキナーゼに対する阻害作用を有さないEGFR阻害剤であることから、この結果はEGF受容体からのシグナル伝達を阻害する物質が心筋分化促進効果を有することを示す。
SO3031(KY01-I)
1H NMR (DMSO-d6): δ 12.61 (s, 1H), 8.37 (s, 1H), 7.73-7.69 (m ,1H), 7.54 (d, J = 8.0 Hz, 1H), 6.97-6.84 (m, 3H), 3.75-3.72 (m, 8H).
MS (ESI) Found; 455 [M+H]+
1H NMR (DMSO-d6): δ 12.42 (s, 1H), 8.37 (s, 1H), 7.72-7.69 (m, 1H), 7.52 (d, J = 8.4 Hz, 1H), 6.85-6.83 (m, 2H), 6.75-6.72 (m, 1H), 3.71 (s, 3H), 3.69 (s, 3H), 2.90-2.76 (m, 4H).
MS (ESI) Found; 469 [M+H]+
1H NMR (DMSO-d6): δ 12.37 (s, 1H), 8.37 (s, 1H), 7.72-7.69 (m, 1H), 7.52 (d, J = 8.4 Hz, 1H), 6.86-6.79 (m, 2H), 6.70 (d, J = 8.0 Hz, 1H), 3.73 (s, 3H), 3.70 (s, 3H), 2.58-2.48 (m, 4H), 1.96-1.86 (m, 2H).
MS (ESI) Found; 483 [M+H]+
1H NMR (DMSO-d6): δ 12.42 (s, 1H), 8.38-8.37 (m, 1H), 7.72-7.69 (m, 1H), 7.54-7.51 (m, 1H), 6.85-6.82 (m, 2H), 6.72 (d, J = 8.0 Hz, 1H), 3.86-3.82 (m, 2H), 3.72 (s, 3H), 2.87-2.78 (m, 4H), 1.72-1.65 (m, 2H), 094 (t, J = 7.3 Hz, 3H).
MS (ESI) Found; 497 [M+H]+
Claims (19)
- EGF受容体阻害剤を含む、多能性幹細胞の心筋分化促進剤。
- EGF受容体阻害剤が、AG1478、ゲフィチニブ、アファチニブ、ARRY334543、AST1306、AZD8931、BIBU1361、BIBX1382、BPDQ、BPIQ-I、BPIQ-II、カネルチニブ、CL-387,785、CUDC101、ダコミチニブ、バンデタニブ、EGFR Inhibitor III(CAS 733009-42-2)、EGFR/ErbB-2 Inhibitor(CAS 179248-61-4)、エルロチニブ、GW583340、GW2974、HDS029、ラパチニブ、WHI-P154、OSI-420、PD153035、PD168393、PD174265、ペリチニブ、Compound 56、XL657、PP3、AG-490、AG555、チロホスチンB42、チロホスチンB44、AG556、AG494、AG825、RG-13022、DAPH、EGFR Inhibitor(CAS 879127-07-8)、エルブスタチンアナログ(CAS 63177-57-1)、JNJ28871063、チロホスチン47、ラベンダスチンA、ラベンダスチンC、ラベンダスチンCメチルエステル、LFM-A12、TAK165、TAK285、チロホスチン51、チロホスチンAG183、チロホスチンAG528、チロホスチンAG99、チロホスチンRG14620、WZ3146、WZ4002、WZ8040、ブテイン、およびチロホスチンAG112から選択される、請求項1記載の心筋分化促進剤。
- EGF受容体阻害剤が、AG1478、ゲフィチニブ、およびPP3から選択される、請求項2記載の心筋分化促進剤。
- 1以上のWntシグナル阻害剤と併用される、請求項1~3のいずれかに記載の心筋分化促進剤。
- Wntシグナル阻害剤が以下の式(I)の化合物またはその塩である、請求項4記載の心筋分化促進剤:
式(I):
R1-R5は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR1-R5のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R6-R9は、各々独立して、水素原子;ハロゲン原子;水酸基;炭素数1~5の直鎖又は分岐アルコキシ基;基-C(O)Aで置換された炭素数1~5の直鎖又は分岐アルコキシ基(Aは、非置換又は炭素数1~5の直鎖または分岐アルキル基で置換された飽和または不飽和5または6員環であり、該環は窒素原子、酸素原子、及び硫黄原子から独立に選択される1または2個の原子を含んでいてもよい);非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基;又は基-NR12R13(R12及びR13は、各々独立して、水素原子、酸素原子、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖または分岐アルキル基である)である、ここでR6-R9のうち隣接する2つが一緒になって-O-CH2-O-または-O-(CH2)2-O-を形成していてもよい、
R10-R11は、各々独立して、水素原子;又は炭素数1~5の直鎖又は分岐アルキル基である、
Xは、-CR14(R14は、水素原子、ハロゲン原子、水酸基、炭素数1~5の直鎖又は分岐アルコキシ基、又は非置換又はハロゲン原子で置換された炭素数1~5の直鎖又は分岐アルキル基である);酸素原子;硫黄原子;セレン原子;又は基-NR15(R15は、水素原子、炭素数1~5の直鎖又は分岐アルキル基、又は炭素数1~5の直鎖又は分岐アシル基である)である、および
nは、0から6の整数である]。 - 式(I)の化合物またはその塩において、
R1、R4、R5、R6、R8、R9、R10及びR11が水素原子である、
R2及びR3が、メトキシ基、エトキシ基、又はプロポキシ基である、
R7が、ハロゲン原子である
Xが、硫黄原子である、および
nが、0から4の整数である、請求項5記載の心筋分化促進剤。 - 式(I)の化合物またはその塩において、
R2が、メトキシ基である、および
R3が、メトキシ基、エトキシ基、又はプロポキシ基である、請求項6記載の心筋分化促進剤。 - Wntシグナル阻害剤がIWP2、XAV939、およびIWR1からなる群から選択される、請求項4に記載の心筋分化促進剤。
- 1以上のWntシグナル活性化剤と併用される、請求項1~9のいずれかに記載の心筋分化促進剤。
- Wntシグナル活性化剤がBIOおよびCHIR99021からなる群から選択される、請求項10記載の心筋分化促進剤。
- EGF受容体阻害剤を含む、心筋分化促進用キット。
- EGF受容体阻害剤を含む培地中で多能性幹細胞を培養することを含む、インビトロにおける多能性幹細胞の心筋分化誘導方法。
- Wntシグナル活性化剤を含む培地中で多能性幹細胞を培養すること、および/またはWntシグナル阻害剤を含む培地中で多能性幹細胞を培養することをさらに含む、請求項13記載の方法。
- 以下の工程を含む、請求項13記載の方法:
(1)多能性幹細胞をWntシグナル活性化剤を含む培地中で培養する工程、および;
(2)工程(1)の後、前記細胞をEGF受容体阻害剤を含む培地中で培養する工程。 - 工程(2)の培養期間の全体または一部において、EGF受容体阻害剤およびWntシグナル阻害剤を含む培地中で細胞を培養する、請求項15記載の方法。
- 培地がアルブミン以外のタンパク質を含まない、請求項13~16のいずれかに記載の方法。
- 浮遊培養により行われる、請求項13~17のいずれかに記載の方法。
- 心筋細胞の製造方法である、請求項13~18のいずれかに記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14760509.1A EP2966166B1 (en) | 2013-03-08 | 2014-02-05 | Promoter of differentiation of pluripotent stem cell into myocardium, which comprises egf receptor inhibitor |
US14/772,991 US10196609B2 (en) | 2013-03-08 | 2014-02-05 | Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor |
JP2015504208A JP6351567B2 (ja) | 2013-03-08 | 2014-02-05 | Egf受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013046591 | 2013-03-08 | ||
JP2013-046591 | 2013-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014136519A1 true WO2014136519A1 (ja) | 2014-09-12 |
Family
ID=51491044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/052673 WO2014136519A1 (ja) | 2013-03-08 | 2014-02-05 | Egf受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10196609B2 (ja) |
EP (1) | EP2966166B1 (ja) |
JP (1) | JP6351567B2 (ja) |
WO (1) | WO2014136519A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015037706A1 (ja) * | 2013-09-13 | 2015-03-19 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化を促進する化合物 |
WO2015182765A1 (ja) * | 2014-05-30 | 2015-12-03 | 国立大学法人京都大学 | 低分子化合物を用いた多能性幹細胞の心筋分化誘導法 |
WO2016119085A1 (zh) * | 2015-01-26 | 2016-08-04 | 东北师范大学 | 对甲氧基桂皮酸乙酯及其衍生物在维持干细胞自我更新和多潜能性中的应用 |
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
US9587220B2 (en) | 2012-01-27 | 2017-03-07 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell |
WO2017159862A1 (ja) | 2016-03-18 | 2017-09-21 | 国立大学法人京都大学 | 多能性幹細胞由来心筋細胞の凝集体の凍結方法 |
WO2018139548A1 (ja) * | 2017-01-26 | 2018-08-02 | 国立大学法人大阪大学 | 幹細胞の中胚葉系細胞への分化誘導用培地および中胚葉系細胞の製造方法 |
US10196609B2 (en) | 2013-03-08 | 2019-02-05 | Kyoto University | Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor |
WO2021251394A1 (ja) * | 2020-06-09 | 2021-12-16 | 株式会社マイオリッジ | 向上した心筋細胞純度を有する心筋細胞集団の製造方法、心筋細胞の純化方法、心筋細胞集団、および移植材料 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220061311A1 (en) * | 2018-11-05 | 2022-03-03 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for reducing cryopreservation toxicity |
WO2021030424A1 (en) * | 2019-08-13 | 2021-02-18 | Semma Therapeutics, Inc. | Pancreatic differentiation |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000508919A (ja) | 1996-04-29 | 2000-07-18 | リューベン・リサーチ・アンド・デベロップメント・ベー・ゼット・ウェー | 多能性ウサギ胚幹(es)細胞系およびそのキメラウサギの発生における使用 |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
WO2009006930A1 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc. | Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue |
US20100183565A1 (en) * | 2008-11-03 | 2010-07-22 | University Of Washington | Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling |
WO2011071118A1 (ja) | 2009-12-09 | 2011-06-16 | 国立大学法人京都大学 | ニトロビンを含む多能性幹細胞の心筋細胞への分化促進剤 |
WO2012026491A1 (ja) | 2010-08-26 | 2012-03-01 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化促進剤 |
WO2013111875A1 (ja) * | 2012-01-27 | 2013-08-01 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化誘導法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63190880A (ja) | 1986-09-09 | 1988-08-08 | Nippon Tokushu Noyaku Seizo Kk | 新規n−ベンゾチアゾリル−アミド類及び殺虫剤 |
US4970318A (en) | 1988-05-24 | 1990-11-13 | Pfizer Inc. | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
IL90337A0 (en) | 1988-05-24 | 1989-12-15 | Pfizer | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
JP2001510450A (ja) | 1996-10-23 | 2001-07-31 | ザイモジェネティクス,インコーポレイテッド | 骨欠損状態を処置するための組成物および方法 |
MXPA02010651A (es) | 2000-04-28 | 2003-03-10 | Sankyo Co | Moduladores de receptor activado de proliferador de peroxisoma-gamma. |
KR101073411B1 (ko) | 2001-07-12 | 2011-10-17 | 제론 코포레이션 | 인간 다분화능 줄기 세포로부터 제조된 심근 세포 계통의 세포 |
BRPI0414961A (pt) | 2003-10-03 | 2006-11-07 | Keiichi Fukuda | processo de indução da diferenciação de células tronco em células do miocárdio |
EP1680431A1 (en) | 2003-10-17 | 2006-07-19 | Rigel Pharmaceuticals, Inc. | Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors |
JP2005330443A (ja) | 2004-05-21 | 2005-12-02 | Fuji Photo Film Co Ltd | セルロース体組成物およびセルロース体フィルム |
CA2595159A1 (en) | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
JP4701382B2 (ja) | 2005-02-09 | 2011-06-15 | 国立大学法人東京農工大学 | 心筋移植片の作製方法及び心筋分化促進剤 |
US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
CN103055313A (zh) | 2005-07-07 | 2013-04-24 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
US7438916B2 (en) | 2005-10-14 | 2008-10-21 | Virginia Tech Intellectual Properties, Inc. | Therapeutic target for protozoal diseases |
GB2447191B (en) | 2005-12-22 | 2011-08-03 | Es Cell Int Pte Ltd | Direct differentiation of cardiomyocytes from human embryonic stem cells |
JP2007252220A (ja) | 2006-03-20 | 2007-10-04 | Cardio Corp | 心筋細胞の製造方法および分化誘導剤 |
GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
JP5149791B2 (ja) | 2006-04-28 | 2013-02-20 | 第一三共株式会社 | 多能性幹細胞から心筋細胞を分化誘導する方法 |
WO2011002950A1 (en) | 2009-07-01 | 2011-01-06 | Trustees Of Dartmouth College | Methods for screening for antibiotic compounds |
WO2011127164A2 (en) | 2010-04-08 | 2011-10-13 | Fate Therapeutics, Inc. | Pharmaceutical compositions to treat fibrosis |
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
WO2014025315A1 (en) * | 2012-08-07 | 2014-02-13 | Singapore Health Services Pte Ltd | Method, combination and/or composition for inducing cardiomyocyte differentation |
EP2966166B1 (en) | 2013-03-08 | 2019-04-03 | Kyoto University | Promoter of differentiation of pluripotent stem cell into myocardium, which comprises egf receptor inhibitor |
WO2015037706A1 (ja) | 2013-09-13 | 2015-03-19 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化を促進する化合物 |
-
2014
- 2014-02-05 EP EP14760509.1A patent/EP2966166B1/en active Active
- 2014-02-05 JP JP2015504208A patent/JP6351567B2/ja active Active
- 2014-02-05 WO PCT/JP2014/052673 patent/WO2014136519A1/ja active Application Filing
- 2014-02-05 US US14/772,991 patent/US10196609B2/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000508919A (ja) | 1996-04-29 | 2000-07-18 | リューベン・リサーチ・アンド・デベロップメント・ベー・ゼット・ウェー | 多能性ウサギ胚幹(es)細胞系およびそのキメラウサギの発生における使用 |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2008118820A2 (en) | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
WO2009006930A1 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc. | Human pluripotent stem cells induced from undifferentiated stem cells derived from a human postnatal tissue |
WO2009006997A1 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc. | Human pluripotent stem cells and their medical use |
WO2009007852A2 (en) | 2007-06-15 | 2009-01-15 | Izumi Bio, Inc | Multipotent/pluripotent cells and methods |
US20100183565A1 (en) * | 2008-11-03 | 2010-07-22 | University Of Washington | Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling |
WO2011071118A1 (ja) | 2009-12-09 | 2011-06-16 | 国立大学法人京都大学 | ニトロビンを含む多能性幹細胞の心筋細胞への分化促進剤 |
WO2012026491A1 (ja) | 2010-08-26 | 2012-03-01 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化促進剤 |
WO2013111875A1 (ja) * | 2012-01-27 | 2013-08-01 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化誘導法 |
Non-Patent Citations (38)
Title |
---|
BIOCHEM BIOPHYS RES COMMUN, vol. 345, no. 3, 2006, pages 926 - 32 |
CELL STEM CELL, vol. 3, 2008, pages 475 - 479 |
CELL STEM CELL, vol. 3, no. 5, 2008, pages 568 - 574 |
CELL STEM CELL, vol. 4, no. 5, 2009, pages 381 - 384 |
CELL, vol. 131, no. 5, 2007, pages 861 - 72 |
CELL, vol. 133, no. 2, 2008, pages 250 - 264 |
CELL, vol. 136, no. 3, 2009, pages 411 - 419 |
DOETSHMAN T. ET AL., DEV. BIOL., vol. 127, 1988, pages 224 - 227 |
EVANS M. J. ET AL., THERIOGENOLOGY, vol. 33, 1990, pages 125 - 128 |
EVANS M. J. ET AL., THERIOGENOLOGY, vol. 33, 1990, pages 125128 |
ITSUNARI MINAMI ET AL.: "Shinki Teibunshi Kagobutsu o Mochiita Hito ES /iPS Saibo no Rinsho Grade Shinkin Bunka Yudoho no Kaihatsu", REGENERATIVE MEDICINE, vol. 12, 28 February 2013 (2013-02-28), pages 151, XP008181336 * |
IWAMOTO, R. ET AL.: "Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function", PROC NATL ACAD SCI U S A., vol. 100, no. 6, 2003, pages 3221 - 6, XP002972137, DOI: doi:10.1073/pnas.0537588100 |
J. MED. CHEM., vol. 8, no. 5, 1965, pages 734 - 735 |
LESCHIK, J. ET AL.: "Cardiac commitment of primate embryonic stem cells", NAT PROTOC., vol. 3, no. 9, 2008, pages 1381 - 7, XP001538578, DOI: doi:10.1038/nprot.2008.116 |
MINAMI, I. ET AL., A SMALL MOLECULE THAT PROMOTES CARDIAC DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS UNDER DEFINED, CYTOKINE- AND XENO-FREE CONDITIONS, CELL REPORTS, vol. 2, 2012, pages 1448 - 1460, XP055097336 * |
MINAMI, I. ET AL.: "A Small Molecule that Promotes Cardiac Differentiation of Human Pluripotent Stem Cells under Defined, Cytokine- and Xeno-free Conditions", CELL REP, vol. 2, no. 5, 25 October 2012 (2012-10-25), pages 1448 - 60, XP055097336, DOI: doi:10.1016/j.celrep.2012.09.015 |
MUMMERY, C. ET AL.: "Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells", CIRCULATION, vol. 107, no. 21, 2003, pages 2733 - 40, XP008029536, DOI: doi:10.1161/01.CIR.0000068356.38592.68 |
NATURE BIOTECHNOLOGY, vol. 26, 2008, pages 1269 - 1275 |
NATURE CELL BIOLOGY, vol. 11, 2009, pages 197 - 203 |
NATURE, vol. 454, 2008, pages 646 - 650 |
NOTARIANNI E. ET AL., J. REPROD. FERT., 1991, pages 255 - 260 |
NOTARIANNI E. ET AL., J. REPROD. FERT., vol. 40, 1990, pages 51 - 56 |
PAUL, W B. ET AL.: "A Universal System for Highly Efficient Cardiac Differentiation of Human Induced Pluripotent Stem Cells That Eliminates Interline Variability", PLOSONE, vol. 6, no. 4, 2011, pages EL8293, XP009167975, DOI: doi:10.1371/journal.pone.0018293 |
PIEDRAHITA J. A. ET AL., THERIOGENOLOGY, vol. 34, 1990, pages 879 - 891 |
SAITO S. ET AL., ROUX. ARCH. DEV. BIOL., vol. 201, 1992, pages 134 - 141 |
SCIENCE, vol. 318, no. 5858, 2007, pages 1917 - 20 |
SHAMBLOTT ET AL., PROC. NATL. ACAD. SCI USA, vol. 95, 1998, pages 13726 - 13731 |
SHEN, G. ET AL., A 2,6-DISUBSTITUTED 4-ANILINOQUINAZOLINE DERIVATIVE FACILITATES CARDIOMYOGENESIS OF EMBRYONIC STEM CELLS, CHEMMEDCHEM, vol. 7, 2012, pages 733 - 740, XP055240274 * |
SUKOYAN M. A. ET AL., MOL. REOROD. DEV., vol. 33, 1993, pages 418 - 431 |
TAKAYUKI MORISAKI: "Shinkin Bunka ni Okeru Bunshi Kaibogakuteki Seigyo Kiko no Kaimei ni Kansuru Kenkyu", ANNUAL REPORT OF THE RESEARCH ON CARDIOVASCULAR DISEASES (HEISEI 15 NENDO), NATIONAL CARDIOVASCULAR CENTER, January 2005 (2005-01-01), pages 177, XP008181719 * |
TALBOT N. C. ET AL., CELL. DEV. BIOL., vol. 29A, 1993, pages 546 - 554 |
THOMSON J. A. ET AL., BIOL. REPROD., vol. 55, 1996, pages 254 - 259 |
THOMSON J. A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 7844 - 7848 |
THOMSON J. A. ET AL., SCIENCE, vol. 282, 1998, pages 1145 - 1147 |
WANG HANMIN ET AL.: "Cardiac Induction of Embryonic Stem Cells by a Small Molecule Inhibitor of Wnt/beta-Catenin Signaling", ACS CHEM. BIOL., vol. 6, 2011, pages 192 - 197, XP055159413 * |
WANG, H. ET AL.: "Cardiac induction of embryonic stem cells by a small molecule inhibitor of Wnt/?-catenin signaling", ACS CHEM BIOL., vol. 6, no. 2, 2011, pages 192 - 7, XP055159413, DOI: doi:10.1021/cb100323z |
WANG, Z. ET AL.: "Neuregulin-1 enhances differentiation of cardiomyocytes from embryonic stem cells", MED. BIOL. ENG. COMPUT., vol. 47, 2009, pages 41 - 48, XP019835287 * |
YANG, L. ET AL.: "Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population", NATURE, vol. 453, no. 7194, 2008, pages 524 - 8, XP002561095, DOI: doi:10.1038/nature06894 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
US9587220B2 (en) | 2012-01-27 | 2017-03-07 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell |
US10196609B2 (en) | 2013-03-08 | 2019-02-05 | Kyoto University | Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor |
WO2015037706A1 (ja) * | 2013-09-13 | 2015-03-19 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化を促進する化合物 |
JPWO2015037706A1 (ja) * | 2013-09-13 | 2017-03-02 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化を促進する化合物 |
US10233426B2 (en) | 2014-05-30 | 2019-03-19 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds |
WO2015182765A1 (ja) * | 2014-05-30 | 2015-12-03 | 国立大学法人京都大学 | 低分子化合物を用いた多能性幹細胞の心筋分化誘導法 |
WO2016119085A1 (zh) * | 2015-01-26 | 2016-08-04 | 东北师范大学 | 对甲氧基桂皮酸乙酯及其衍生物在维持干细胞自我更新和多潜能性中的应用 |
US10723998B2 (en) | 2015-01-26 | 2020-07-28 | Northeast Normal University | Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells |
WO2017159862A1 (ja) | 2016-03-18 | 2017-09-21 | 国立大学法人京都大学 | 多能性幹細胞由来心筋細胞の凝集体の凍結方法 |
US12018280B2 (en) | 2016-03-18 | 2024-06-25 | Kyoto University | Method for freezing aggregates of pluripotent stem cell-derived cardiomyocytes |
WO2018139548A1 (ja) * | 2017-01-26 | 2018-08-02 | 国立大学法人大阪大学 | 幹細胞の中胚葉系細胞への分化誘導用培地および中胚葉系細胞の製造方法 |
JPWO2018139548A1 (ja) * | 2017-01-26 | 2019-11-14 | 国立大学法人大阪大学 | 幹細胞の中胚葉系細胞への分化誘導用培地および中胚葉系細胞の製造方法 |
JP7162537B2 (ja) | 2017-01-26 | 2022-10-28 | 国立大学法人大阪大学 | 幹細胞の中胚葉系細胞への分化誘導用培地および中胚葉系細胞の製造方法 |
WO2021251394A1 (ja) * | 2020-06-09 | 2021-12-16 | 株式会社マイオリッジ | 向上した心筋細胞純度を有する心筋細胞集団の製造方法、心筋細胞の純化方法、心筋細胞集団、および移植材料 |
Also Published As
Publication number | Publication date |
---|---|
US20160002600A1 (en) | 2016-01-07 |
EP2966166A4 (en) | 2016-11-16 |
US10196609B2 (en) | 2019-02-05 |
JPWO2014136519A1 (ja) | 2017-02-09 |
JP6351567B2 (ja) | 2018-07-04 |
EP2966166A1 (en) | 2016-01-13 |
EP2966166B1 (en) | 2019-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6351567B2 (ja) | Egf受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 | |
JP6651218B2 (ja) | 低分子化合物を用いた多能性幹細胞の心筋分化誘導法 | |
JP6274510B2 (ja) | 多能性幹細胞の心筋分化誘導法 | |
JP5930205B2 (ja) | 多能性幹細胞の心筋分化促進剤 | |
US9499790B2 (en) | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells | |
US8822684B1 (en) | Compounds and methods useful for directing stem cell differentiation | |
WO2017159862A1 (ja) | 多能性幹細胞由来心筋細胞の凝集体の凍結方法 | |
KR100980005B1 (ko) | 배아줄기세포를 심근세포로 분화 유도하는 방법 | |
WO2011071118A1 (ja) | ニトロビンを含む多能性幹細胞の心筋細胞への分化促進剤 | |
KR100948170B1 (ko) | 배아줄기세포를 혈관모세포로 분화 유도하는 방법 | |
JP6333830B2 (ja) | 多能性幹細胞の心筋分化を促進する化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14760509 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14772991 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015504208 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014760509 Country of ref document: EP |